Menopause Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Menopause is defined as the permanent cessation of menstruation due to loss of ovarian follicular activity — diagnosed retrospectively after 12 consecutive months of amenorrhoea. The average age of natural menopause is 51 years in Western populations (range 45–55). Perimenopause — the transitional phase preceding menopause — typically begins 4–6 years before the final menstrual period, characterised by menstrual irregularity, fluctuating oestrogen levels, and emerging menopausal symptoms. Premature ovarian insufficiency (POI) refers to menopause before age 40 — affecting 1% of women, and associated with significantly higher long-term health risks (osteoporosis, cardiovascular disease, dementia) requiring prompt treatment.

Menopause is not a disease — it is a natural biological transition — but the oestrogen deficiency that accompanies it has well-documented consequences across multiple body systems: vasomotor symptoms (hot flushes and night sweats — affecting 70–80% of women); sleep disturbance; genitourinary syndrome of menopause (GSM — vulvovaginal atrophy, vaginal dryness, dyspareunia, urinary urgency and frequency — affecting 50–60% of postmenopausal women); musculoskeletal symptoms (joint pain, reduced muscle mass); mood changes, anxiety, and cognitive symptoms (brain fog); accelerated bone loss (2–5% per year in the first 5 years post-menopause); and unfavourable changes in cardiovascular risk factors (lipid profile shift, increased blood pressure).

Hormone replacement therapy (HRT) — administering oestrogen (with progestogen if the uterus is intact) — remains the most effective treatment for menopausal symptoms and has additional documented benefits for bone, cardiovascular, and genitourinary health. The risk-benefit balance of HRT has been extensively re-evaluated following the WHI study — modern evidence with body-identical hormones supports HRT's safety for most healthy women under 60 or within 10 years of menopause. Non-hormonal options are available for women with absolute contraindications to HRT or who prefer to avoid it.

• Vasomotor symptoms (VMS) — hot flushes and night sweats: The most common and distressing menopausal symptoms, affecting 70–80% of women and persisting for a median of 7–10 years (longer in some women). Hot flushes: sudden onset feeling of intense heat spreading from chest to face and neck, often accompanied by perspiration, palpitations, and anxiety; last 1–5 minutes; can occur 10–20+ times daily in severe cases. Night sweats: nocturnal vasomotor episodes disrupting sleep quality, leading to fatigue, mood disturbance, and impaired cognitive function. HRT reduces VMS by 75–90% — the most effective treatment available. Non-hormonal: fezolinetant (Veoza, 45 mg/day — NK3R antagonist, FDA/EMA approved 2023 specifically for moderate-severe VMS); SSRIs/SNRIs (escitalopram, venlafaxine, desvenlafaxine — 40–60% VMS reduction); gabapentin (40–60% reduction); oxybutynin; clonidine (modest effect, side effect-prone).
• Genitourinary syndrome of menopause (GSM): Encompasses all vulvovaginal and lower urinary tract changes due to oestrogen deficiency: vaginal dryness, dyspareunia (painful intercourse), vaginal itching/burning, reduced vaginal lubrication, shortened vaginal length, urinary urgency and frequency, increased UTI susceptibility, and stress/urgency urinary incontinence. Unlike VMS (which may resolve spontaneously), GSM is progressive and worsens without treatment. Local (vaginal) oestrogen (cream, pessary, ring, tablet) is safe and highly effective for GSM — not significantly absorbed systemically; can be used even when systemic HRT is not appropriate (including most breast cancer survivors, per RCOG 2020 guidance). Intrarosa (prasterone/DHEA vaginal inserts) and ospemifene (oral SERM) are non-oestrogen options approved specifically for GSM with dyspareunia.
• Mood disturbance, anxiety, and cognitive symptoms: Perimenopause is associated with increased vulnerability to depression and anxiety — oestrogen influences serotonin, noradrenaline, and dopamine neurotransmission. Mild-moderate mood symptoms: HRT (transdermal oestrogen + progestogen) has demonstrated mood-improving benefit in perimenopausal women (MEANTIME trial); physical exercise; CBT. Clinical depression: antidepressants (SSRIs/SNRIs) — note: antidepressants are also effective for VMS, offering dual benefit in women with both depression and hot flushes. Cognitive symptoms (brain fog, word finding difficulty, memory lapses): common during perimenopause, generally resolves post-menopause; HRT may provide modest cognitive protection, particularly when started near menopause (critical window hypothesis).
• Bone loss and osteoporosis prevention: HRT prevents menopausal bone loss — maintained bone density during treatment; hip and vertebral fracture risk reduced by 30–34% (WHI data). HRT is therefore appropriate for osteoporosis prevention in younger menopausal women (<60 or within 10 years of menopause). Women who stop HRT experience a return to bone loss trajectory. For established osteoporosis, bisphosphonates, denosumab, or anabolic agents are recommended (see Osteoporosis Treatment profile) — HRT can be used adjunctively if symptom management is also indicated.

HRT is appropriate for:

• Women with significant menopausal symptoms — particularly VMS and GSM — impairing quality of life
• Women under 60 or within 10 years of menopause onset — risk-benefit is most favourable in this group ('timing hypothesis')
• Women with premature ovarian insufficiency (POI — menopause before 40) — HRT mandatory until age 51 for cardiovascular and bone protection
• Women with surgical menopause (bilateral oophorectomy) before natural menopause age — systemic HRT recommended
• DEXA-confirmed osteoporosis or high FRAX fracture risk in women who also have menopausal symptoms — HRT provides dual benefit

Contraindications to systemic HRT:

• Current or recent oestrogen receptor-positive breast cancer (relative or absolute depending on stage and treatment)
• Active or recent arterial thromboembolic event (MI, stroke) — within 12 months; not indefinite contraindication
• Active endometrial cancer or untreated endometrial hyperplasia with atypia
• Active liver disease with abnormal liver function tests
• Undiagnosed abnormal vaginal bleeding
• Note: VTE history is NOT an absolute contraindication to HRT — transdermal oestrogen (patch, gel, spray) does not increase VTE risk (unlike oral oestrogen) and can be used with appropriate haematological assessment

Progestogen co-administration requirement: Women with an intact uterus must take progestogen alongside oestrogen to prevent endometrial hyperplasia and cancer. Progestogen options: continuous combined (no withdrawal bleed; suitable for postmenopause >12 months amenorrhoea); sequential combined (cyclical withdrawal bleed; appropriate for perimenopause/early post-menopause). Micronised progesterone (Utrogestan, Prometrium — body-identical/bioidentical) preferred over synthetic progestogens — associated with lower breast cancer risk signal and VTE risk vs. synthetic progestogens.

Management of Menopause Treatment is individualised based on disease severity, patient age, comorbidities, and patient values. The gynaecological team develops a personalised plan incorporating the following evidence-based treatment modalities:

• Conservative and lifestyle-based management: For many presentations, targeted lifestyle modification — including nutritional optimisation, graded physical activity, weight management, alcohol and smoking cessation — forms the foundation of care. Regular specialist monitoring and patient self-management education enable early detection of deterioration and empower patients to actively participate in their treatment.
• Pharmacological therapy: Evidence-based drug therapy tailored to disease mechanism and individual patient profile forms the pharmacological backbone. First-line agents are selected per current international guidelines, with treatment escalated to second-line or combination therapy for inadequate responders. Regular monitoring ensures therapeutic efficacy and detects adverse effects early.
• Procedural and interventional approaches: Where pharmacological management is insufficient or specific structural or functional abnormalities are identified, minimally invasive or interventional procedures are considered. These are performed by experienced gynaecological specialists at accredited facilities with appropriate pre-procedure preparation and post-procedure monitoring protocols.
• Surgical treatment: Surgery is indicated for patients with advanced disease, complications, or conditions unresponsive to medical management. Modern surgical approaches include laparoscopic, robotic-assisted, and image-guided techniques that minimise operative morbidity and accelerate recovery. Surgical decisions are made following multidisciplinary discussion and informed consent.
• Multidisciplinary team (MDT) care: Complex presentations are managed through an MDT integrating expertise from relevant specialties — gynaecological medicine, radiology, physiotherapy, nutrition, psychology, and palliative care as appropriate. MDT-driven care demonstrably improves outcomes for complex conditions. Patient and family involvement in MDT planning ensures alignment with individual values.
• Emerging and clinical trial options: Access to investigational treatments through clinical trials at specialist centres offers patients with refractory or high-risk presentations the opportunity to access next-generation therapies under systematic monitoring. Trial eligibility is assessed as part of the MDT plan.

• Symptom relief — HRT: Transdermal or oral oestrogen reduces hot flush frequency by 75–90% and severity by 87% (Cochrane meta-analysis, 24 RCTs). Night sweat frequency reduced 87%. Quality-of-life improvements across all menopausal symptom scales (Greene Climacteric Scale, MRS). These benefits are typically experienced within 2–4 weeks of starting HRT, with maximum benefit at 3 months.
• Cardiovascular benefits of early initiation: The 'timing hypothesis' (Rossouw et al., WHI reanalysis) demonstrates that HRT initiated within 10 years of menopause or before age 60 is associated with cardiovascular benefit — approximately 30% reduction in coronary heart disease events (DOPS trial, Danish Osteoporosis Prevention Study: 10 years of HRT, initiated at menopause, associated with 52% reduction in composite cardiovascular outcomes at 16-year follow-up). Transdermal oestrogen does not increase VTE or stroke risk (no first-pass hepatic effect). HRT initiated in women already many years postmenopause may not confer cardiovascular benefit and could transiently increase risk — the basis of the unfavourable WHI findings in an older population.
• Fezolinetant — first non-hormonal neurokinin-3 receptor antagonist: Fezolinetant (Veoza 45 mg/day, FDA/EMA approved 2023) works by blocking the NK3R receptor in the hypothalamus involved in body temperature regulation — directly targeting the thermoregulatory pathway responsible for hot flushes without any hormonal effect. Achieves 74% reduction in moderate-severe hot flush frequency at 12 weeks (SKYLIGHT 1&2 trials). An important advance for women who cannot or choose not to use HRT.
• Vaginal oestrogen for GSM — lifelong safe use: Low-dose local vaginal oestrogen (Vagifem, Estring, Ovestin) reverses GSM — restores vaginal pH, epithelial thickness, lubrication, and flora — achieving 60–80% improvement in dyspareunia and vaginal dryness at 3 months. Unlike systemic HRT, serum oestrogen levels with vaginal oestrogen preparations remain within the postmenopausal range — systemic absorption is minimal. RCOG 2020 and ACOG guidelines support vaginal oestrogen use in most breast cancer survivors (discuss with oncologist for hormone-sensitive breast cancer on aromatase inhibitor). Treatment can be continued indefinitely as long as GSM symptoms persist — GSM does not resolve without treatment.

• Breast cancer risk — HRT: The most discussed HRT risk. Evidence: Million Women Study (observational): combined oestrogen + progestogen HRT associated with small increased relative breast cancer risk after 5+ years use. Collaborative Group (2019 Lancet meta-analysis): longer duration of use associated with higher risk; risk returns to baseline approximately 5 years after stopping; current HRT users: approximately 1 extra breast cancer per 50 users at 10 years for combined HRT. Context: obesity, alcohol (>1 unit/day), sedentary lifestyle, and nulliparity each carry comparable or greater breast cancer risks to 5 years of combined HRT use. Oestrogen-only HRT (in hysterectomised women): neutral or possibly slightly protective for breast cancer (WHI E-alone trial). Micronised progesterone + oestrogen: preliminary evidence of lower breast cancer signal than synthetic progestogens (E3N French cohort) — not yet RCT-level evidence.
• VTE risk: Oral oestrogen (tablets): 2–3× VTE risk increase (similar absolute risk to combined OCP in young women — approximately 2 extra VTE events per 1,000 women per year). Transdermal oestrogen (patch, gel, spray): does NOT increase VTE risk (no first-pass liver effect; no increase in clotting factor synthesis). Women with prior VTE, thrombophilia, or high VTE risk should use transdermal oestrogen if HRT is desired. Micronised progesterone or dydrogesterone: lower VTE risk signal vs. other progestogens — preferred combination for higher VTE risk women.
• Stroke risk: Oral oestrogen: small increased ischaemic stroke risk (RR 1.3–1.5 in observational data). Transdermal oestrogen: no significant stroke risk increase (Renoux 2010, BMJ). For women with prior stroke or high cerebrovascular risk — transdermal oestrogen + body-identical progesterone is preferred if HRT indicated.
• Progestogen side effects: Mood changes (particularly premenstrual-type symptoms with synthetic progestogens — less with micronised progesterone); breast tenderness; bloating; acne. Breakthrough bleeding during sequential phase — common in early use; investigate if persistent beyond 6 months.
• SERM and non-hormonal agent risks: Ospemifene: modest increased VTE risk (not contraindicated with prior VTE unless active); avoidance in oestrogen receptor-positive breast cancer. SSRIs: sexual dysfunction (reduced libido, anorgasmia) can worsen GSM-related sexual dysfunction. Gabapentin: dizziness, sedation, cognitive effects — limit daytime use.

Treatment response monitoring: Following initiation of Menopause Treatment, clinical response is assessed at 4–12 weeks. Objective parameters (laboratory values, imaging, functional assessments) and symptom scores are tracked; treatment is adjusted based on response and tolerability.

Regular specialist review: Ongoing management requires specialist appointments every 3–6 months once stable, with more frequent reviews during treatment initiation, dose adjustment, or when complications arise. Each visit includes clinical assessment, medication review, and complication screening.

Long-term monitoring: Annual comprehensive review including laboratory investigations, imaging as indicated, quality-of-life assessment, and screening for disease-related complications. Lifelong healthy lifestyle behaviours and regular check-ins with primary care complement specialist follow-up to ensure continuity of care and early detection of any deterioration.

Menopause management is predominantly outpatient-based. India offers very affordable access to specialist gynaecological care and HRT medications:

• India: Gynaecologist / menopause specialist consultation: USD 15–50. Generic oestrogen patch (Evorel/Climara equivalent): USD 15–40/month. Vaginal oestrogen cream (Premarin/Ovestin): USD 5–15/month. Micronised progesterone (Utrogestan generic): USD 20–50/month. Annual HRT (transdermal oestrogen + micronised progesterone): USD 200–600. DEXA bone scan: USD 30–80. Testosterone gel (off-label for low libido — limited Indian availability): USD 30–80/month. India's menopause clinics — at Apollo, Fortis, Cloudnine, major teaching hospitals — provide comprehensive menopause consultations including hormone level testing, bone density assessment, and individualised HRT prescribing. The Indian Menopause Society provides guidelines for Indian clinical practice.
• Thailand: Menopause specialist consultation: USD 50–100. Combined HRT (patch + oral progestogen): USD 50–100/month. Vaginal oestrogen: USD 20–50/month.
• United Kingdom (NHS): HRT prescriptions available on NHS — single prescription charge covers entire HRT prescription (one charge regardless of number of items since 2023 NHS menopause policy change). Specialist menopause clinic referral via GP. NICE NG23 guideline mandates access to menopause care. Vaginal oestrogen: available on NHS prescription. NHS menopause app and NICE guidance freely accessible.
• United States: Estradiol patch (generic Climara, 0.05 mg/week): USD 30–80/month. Estradiol gel (Divigel, Estrogel): USD 80–200/month. Progesterone capsule (generic Prometrium 100 mg): USD 30–80/month. Fezolinetant (Veoza): USD 500–600/month (launched 2023; insurance coverage variable). Annual menopause specialist management: USD 500–2,000. Vaginal oestrogen: USD 50–150/month (ring), USD 30–80/month (tablet/cream).

Alternative or complementary approaches may be considered for patients unsuitable for standard Menopause Treatment, preferring less intensive treatment, or seeking additional options alongside conventional care:

• Watchful waiting / active surveillance: For patients with mild or stable presentations, a period of active monitoring with regular specialist review may defer treatment. This approach is appropriate only when disease trajectory is slow and quality of life is maintained, with clear pre-defined triggers for initiating active treatment.
• Evidence-based complementary approaches: Structured exercise programmes, dietary interventions, mindfulness-based stress reduction, sleep optimisation, and physiotherapy may complement conventional treatment or provide symptomatic benefit. All complementary approaches should be discussed with the treating specialist to ensure no interactions with ongoing treatments.
• Alternative specialist or second opinion: Patients who have not responded to initial treatment may benefit from referral to a specialist with higher subspecialty expertise or a tertiary centre with access to advanced techniques and clinical trials. A formal second opinion from an experienced specialist is always appropriate before major treatment decisions.
• Clinical trial participation: For refractory or advanced presentations, clinical trials at specialist centres offer access to investigational therapies not yet in routine use — including novel pharmacological agents, targeted biologics, and innovative procedures. Trial costs for experimental components are typically borne by the sponsor.
• Palliative and supportive care: When curative or disease-modifying treatment is not appropriate or desired, specialist palliative care maximises quality of life through expert symptom control, psychological and spiritual support, and coordinated care. Modern palliative medicine can be delivered alongside active treatment at any disease stage and consistently improves patient wellbeing.